Select Bibliography

Filter by any of these (after searching):

There are 133 items

A good prognosis of endocrine-dependent tumors among residual invasive cancer after anti-HER2 therapy: CALGB 40601 (Alliance) and validation studies

Ahn, Sung Gwe , Fernandez-Martinez, Aranzazu , Prat, Aleix ... - SABCS - Cancer Res - 2020

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-40601

Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147.

Alberts, S. R. , Thibodeau, S. N. , Sargent, D. J. , Mahoney, M. R. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Secondary - Primary - Correl Sci NOS - NCCTG-N0147

Par-4 Down-regulation Promotes Breast Cancer Recurrence by Preventing Multinucleation following Targeted Therapy

Alvarez, James V. , Pan, Tien-chi , Ruth, Jason , Feng, Yi ... - - Cancer Cell - 2013

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-150007

Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance).

Anurag, Meenakshi , Zhu, Mayanne , Huang, Chen , Vasaikar, Suhas ... - - J. Natl. Cancer Inst. - 2020

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - ACOSOG-Z1031

Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance)

Augert, Arnaud , Zhang, Qing , Bates, Breanna , Cui, Min ... - - J Thorac Oncol - 2017

Manuscript - Secondary - Primary - Correl Sci NOS - CALGB-151111

Her2 gene expression and not Her2 amplification is predictive and prognostic in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405 (Alliance)

Battaglin, Francesca , Ou, Fang-Shu , Qu, Xueping ... - ASCO - J. Clin. Oncol - 2020

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-80405

Comparison of Clinical and Biologic Significance of WT1 Mutations in Populations of Older (>= 60 years y ) and Younger (< 60 y) Adult Patients (Pts) with Cytogenetically Normal (CN) De Novo Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study

Becker, H. , Marcucci, G. , Maharry, K. , Radmacher, M. D. ... - - Blood - 2009

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-20502 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720

Activating Mutations in PIK3CA or AKT1 in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)

Boudreau, A. , Yau, C. , Petrillo, L. , Stemke-Hale, K. , Mills, G. ... - SABCS - Cancer Res. - 2011

Abstract - Secondary - Primary - Correl Sci NOS - ACRIN-6657 , CALGB-150007

Multi-institutional prospective validation of prognostic mRNA signatures in early stage squamous lung cancer (Alliance).

Bueno, Raphael , Richards, William G , Harpole, David H ... - - J Thorac Oncol - 2020

Manuscript - Primary - Meta-Analysis - Correl Sci NOS - CALGB-150807 , CALGB-140202

The Prognostic Implications of Macrophages Expressing Proliferating Cell Nuclear Antigen in Breast Cancer Depend on Immune Context

Campbell, Michael J. , Wolf, Denise , Mukhtar, Rita A. ... - - PLoS ONE - 2013

Manuscript - Secondary - Primary - Correl Sci NOS - CALGB-150007

Impact of KRAS mutations on adjuvant carboplatin/paclitaxel in surgically resected stage IB NSCLC: CALGB 9633

Capelletti, M. , Wang, X. F. , Gu, L. , Graziano, S. L. ... - - J. Clin. Oncol. - 2010

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-9633

High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance)

Chumsri, Saranya , Sperinde, Jeff , Liu, Heshan , Gligorov, Joseph ... - - Clin. Cancer Res. - 2018

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0337 , N98-32-52

Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I-SPY trial (CALGB 150007/150015/ACRIN6657)

Clark, Amy S , Chen, Jinbo , Kapoor, Shiv , Friedman, Claire ... - - Cancer Med - 2014

Manuscript - Secondary - Primary - Correl Sci NOS - CALGB-150007

Coagulation factors in citrated plasma predict for benefit from bevacizumab (B) in patients with advanced pancreatic cancer (APC): Results from CALGB 80303 (Alliance)

Clarke, Jeffrey M. , Pang, Herbert , Starr, Mark D. , Hatch, Ace ... - ASCO GI - J. Clin. Oncol. - 2015

Abstract - Secondary - Primary - Correl Sci NOS - CALGB-80303

Loss of p27 expression and response to neoadjuvant chemotherapy: Results from the I-SPY Trial (CALGB150007/150012, ACRIN6657)

Demichele, A. , Dunn, L. , Gimotty, P. , Livasy, C. , Perou, C. ... - ASCO - J Clin Oncol - 2009

Abstract - Secondary - Primary - Correl Sci NOS - CALGB-150007

Comparison of community and central Her2 assessment on outcome of neoadjuvant chemotherapy in the I-SPY trial (CALGB 150007/150012, ACRIN 6657)

Demichele, A. , Yau, C. , Zhu, J. , Wuhfkuhle, J. , Lenburg, M. E. ... - SABCS - Cancer Res. - 2011

Abstract - Secondary - Primary - Correl Sci NOS - ACRIN-6657 , CALGB-150007

Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.

DiGiovanna, Michael P , Stern, David F , Edgerton, Susan ... - - J. Clin. Oncol. - 2008

Manuscript - Secondary - Primary - Correl Sci NOS - C8541

CYFRA 21-1 as a prognostic and predictive marker in advanced non-small cell lung cancer in a prospective trial: CALGB 150304

Edelman, Martin J. , Hodgson, Lydia , Rosenblatt, Paula Y. ... - - J Thorac Oncol - 2012

Manuscript - Secondary - Primary - Correl Sci NOS - CALGB-150304

Tumor Ki67 Proliferation Index within 4 Weeks of Initiating Neoadjuvant Endocrine Therapy for Early Identification of Non-Responders

Ellis, M. , Luo, J. , Tao, Y. , Hoog, J. , Snider, J. , DeSchryver, K. ... - - Cancer Research - 2009

Abstract - Secondary - Primary - Correl Sci NOS - ACOSOG-Z1031

Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer

Ellis, Matthew J , Lin, Li , Crowder, Robert , Tao, Yu , Hoog, Jeremy ... - - Breast Cancer Res Treat - 2010

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - ACOSOG-Z1031

Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657

Esserman, L. J. , Berry, D. A. , Demichele, A. , Carey, L. ... - - J. Clin. Oncol. - 2012

Manuscript - Secondary - Primary - Correl Sci NOS - CALGB-150007 , CALGB-150012 , ACRIN-6657

Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY Trial (CALGB 150007/150012, ACRIN 6657)

Esserman, L. J. , Perou, C. M. , Cheang, M. , Demichele, A. ... - - J. Clin. Oncol. - 2009

Abstract - Secondary - Primary - Correl Sci NOS - ACRIN-6657 , CALGB-150007

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

Esserman, Laura J. , Berry, Donald A. , Cheang, Maggie C. U. ... - - Breast Cancer Res. Treat - 2012

Manuscript - Secondary - Primary - Correl Sci NOS - CALGB-150007

Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial.

Filho, Otto Metzger , Stover, Daniel G , Asad, Sarah ... - - JAMA Oncol - 2021

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - AFT-04

Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance)

George, Daniel.J. , Halabi, Susan , Nixon, Andrew B. , Starr, Mark D. ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary - Primary - Correl Sci NOS - CALGB-90206

Sentinel node biopsy performed in the neoadjuvant setting for Breast Cancer: Results from the CALGB 150007 & 150012/ACRIN 6657 I-SPY TRIAL

Gomez, R. , Zakhireh, J. , Moore, D. , Demichelle, A. , Przewoznik, J. ... - SABCS - Cancer Res. - 2009

Abstract - Secondary - Primary - Correl Sci NOS - ACRIN-6657 , CALGB-150007

Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147

Gonsalves, Wilson I. , Mahoney, Michelle R. , Sargent, Daniel J. ... - - J. Natl. Cancer Inst - 2014

Manuscript - Secondary - Primary - Correl Sci NOS - N0147

Prognostic significance of molecular markers and clinical factors in stage IB non-small cell lung cancer (NSCLC): A laboratory companion study to CALGB 9633

Graziano, S. L. , Gu, L. , Wang, X. , Tatum, A. , Vollmer, R. T. ... - - J Thorac Oncol - 2007

Abstract - Secondary - Primary - Correl Sci NOS - CALGB-159802 , CALGB-9633

Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.

Haricharan, Svasti , Punturi, Nindo , Singh, Purba ... - - Cancer Discov - 2017

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - ACOSOG-Z1031

Topoisomerase IIα Amplification Does Not Predict Benefit From Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy in HER2-Amplified Early Breast Cancer: Results of CALGB 8541/150013

Harris, Lyndsay N. , Broadwater, Gloria , Abu-Khalaf, Maysa ... - - J. Clin. Oncol - 2009

Manuscript - Secondary - Primary - Correl Sci NOS - CALGB-150013 , C8541

Blood‐based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)

Hatch, Ace J. , Sibley, Alexander B. , Starr, Mark D. ... - - Cancer Med - 2016

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-80203

Genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer

Hatzis, Christos , Pusztai, Lajos , Valero, Vicente ... - - JAMA - 2011

Manuscript - Secondary - Primary - Correl Sci NOS - CALGB-150007

HER2 and response to paclitaxel in node-positive breast cancer.

Hayes, Daniel F , Thor, Ann D , Dressler, Lynn G , Weaver, Donald ... - - N. Engl. J. Med. - 2007

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-9344

Multivariate Analysis of Subtype and Gene Expression Signatures Predictive of Pathologic Complete Response (pCR) in Triple-Negative Breast Cancer (TNBC): CALGB 40603 (Alliance)

Hoadley, Katherine A. , Hyslop, Terry , Fan, Cheng , Berry, Donald A. ... - SABCS - Cancer Res - 2017

Abstract - Secondary - Primary - Correl Sci NOS - CALGB-40603

Mutational Analysis of Triple-Negative Breast Cancer (TNBC): CALGB 40603 (Alliance)

Hoadley, Katherine A. , Powell, Bradford C. , Kanavy, Dona ... - SABCS - Cancer Res - 2019

Abstract - Secondary - Primary - Correl Sci NOS - CALGB-40603

Biologic Prognostic Markers in Diffuse Large B-Cell Lymphoma Patients Treated with Dose Adjusted EPOCH-R: a CALGB 50103 Correlative Science Study

Hsi, E. D. , Said, J. , Johnson, J. L. , Jung, S. , Lai, R. , Jones, D. ... - ASH - Blood - 2008

Abstract - Secondary - Primary - Correl Sci NOS - CALGB-50103

Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome

Innocenti, Federico , Ou, Fang-Shu , Qu, Xueping , Zemla, Tyler J. ... - - J. Clin. Oncol - 2019

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-80405

Somatic DNA mutations, mutational load (ML), and MSI status: association with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance)

Innocenti, Federico , Ou, Fang-Shu , Zemla, Tyler ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary - Primary - Correl Sci NOS - CALGB-80405

ARID1A mutations induce an EGFR-like gene expression signature and confer intrinsic and acquired resistance to cetuximab treatment in first line metastatic CRC (Alliance)

Johnson, Radia M. , Qu, Xueping , Thomas, Joshua , Kschonsak, Yvonne ... - AACR - Cancer Res - 2020

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-80405

CALGB 150002: Correlation of HER-2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840: Paclitaxel (P) +/-T in HER-2(+) and (-) metastatic breast cancer (MBC)

Kaufman, P. A. , Broadwater, G. , Lezon-Geyda, K. A. ... - - J. Clin. Oncol. - 2007

Abstract - Secondary - Primary - Correl Sci NOS - C150002

Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS

Kim, Kyu-pyo , Parise, Robert A. , Holleran, Julianne L. ... - - J Pharm Biomed Anal - 2017

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - A031201

Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: results from two prospective cohorts and CALGB 89803 Alliance) trial

Kosumi, Keisuke , Hamada, Tsuyoshi , Zhang, Sui , Liu, Li ... - - Eur. J. Cancer - 2019

Manuscript - Secondary-not-in-original - Meta-Analysis - Correl Sci NOS - CALGB-89803

High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlative study.

Lai, Raymond , Bartlett, Nancy L , Mackey, John R , Jung, Sin-Ho ... - - Leuk. Lymphoma - 2008

Manuscript - Secondary - Primary - Correl Sci NOS - CALGB-59804

Multicenter I-SPY 1 TRIAL (CALGB 150007/150012): Breast cancer stem cells are associated with intrinsic chemoresistance and worse survival

Landis, M. , Yau, C. , Neumeister, V. , Rimm, D. , Esserman, L. ... - - Cancer Res. - 2012

Abstract - Secondary - Primary - Correl Sci NOS - CALGB-150007 , CALGB-150012

p53 Expression in Node Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B (CALGB) 9344 Trial (159905)

Lara, Jonathan F. , Thor, Ann D. , Dressler, Lynn G. ... - - Clin Cancer Res - 2011

Manuscript - Secondary - Primary - Correl Sci NOS - CALGB-159905 , CALGB-9344

Validation of DPYD variants DPYD*2A, I560S, and D949V as predictors of 5-fluorouracil (5-FU)-related toxicity in stage III colon cancer (CC) patients from adjuvant trial NCCTG N0147

Lee, A. , Shi, Q. , Pavey, E. , Sargent, D. J. , Alberts, S. R. ... - - J. Clin. Oncol. - 2013

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147

HapB3 and the deep intronic variant c.1129-5923 C>G of the dihydropyrimidine dehydrogenase gene (DPYD) as predictors of toxicity in Stage III colon cancer (CC) patients (pts) (NCCTG N0147) (Alliance)

Lee, Adam M. , Shi, Qian , Alberts, Steven R. , Sargent, Daniel J. ... - ASCO GI - J. Clin. Oncol. - 2015

Abstract - Secondary - Primary - Correl Sci NOS - N0147

Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)

Lee, Adam M. , Shi, Qian , Alberts, Steven R. , Sargent, Daniel J. ... - - Pharmacogenet. Genomics - 2016

Manuscript - Secondary - Primary - Correl Sci NOS - N0147

DPYD Variants as Predictors of 5-fluorouracil Toxicity in Adjuvant Colon Cancer Treatment (NCCTG N0147)

Lee, Adam M. , Shi, Qian , Pavey, Emily , Alberts, Steven R. ... - - J. Natl. Cancer Inst - 2014

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147

Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147) (Alliance)

Lee, H. , Sha, D. , Foster, N. R. , Shi, Q. , Alberts, S. R. ... - - Ann. Oncol. - 2020

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147

Association of micropapillary architecture and high tumor budding with prognosis in patients with stage III colon cancer from a FOLFOX-based adjuvant chemotherapy trial: NCCTG N0147 (Alliance)

Lee, Hee Eun , Shi, Qian , Foster, Nate , Chan, Emily , Gill, Sharlene ... - USCAP - Mod Pathol - 2017

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147

Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer

Lei, Jonathan T. , Shao, Jieya , Zhang, Jin , Iglesia, Michael ... - - Cell Rep - 2018

Manuscript - Secondary - Primary - Correl Sci NOS - ACOSOG-Z1031

Impact of Consensus Molecular Subtyping (CMS) on overall survival (OS) and Progression Free Survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance).

Lenz, Heinz-Josef , Ou, Fang-Shu , Venook, Alan P. ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-80405

Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).

Lenz, Heinz-Josef , Ou, Fang-Shu , Venook, Alan P ... - - J. Clin. Oncol. - 2019

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - A151425 , CALGB-80405

RANK expression in primary tumor tissue at the time of diagnosis correlates with risk of subsequent bone metastases in the I-SPY 1 trial (CALGB 150007/150012; ACRIN 6657)

Li, J. , Yau, C. , Campbell, M. , Park, J. W. ... - SABCS - Cancer Res. - 2011

Abstract - Secondary - Primary - Correl Sci NOS - ACRIN-6657 , CALGB-150007

Detection of locally advanced breast cancer in the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657) in the interval between routine screening

Lin, C. , Moore, D. , Demichele, A. , Ollila, D. W. ... - - J. Clin. Oncol. - 2009

Abstract - Secondary - Primary - Correl Sci NOS - CALGB-150007

Semi-quantitative protein analysis of HER2 and ER levels in human breast cancer reveals broad expression ranges within HER2+ and ER+ phenotypes

Liotta, L. , Pierobon, M. , Wulfkuhle, J. , Laird, J. , Livasy, C. ... - ASCO - J. Clin. Oncol. - 2009

Abstract - Secondary - Primary - Correl Sci NOS - CALGB-150007

Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer

Lips, Esther H. , Mukhtar, Rita A. , Yau, Christina ... - - Breast Cancer Res. Treat. - 2012

Manuscript - Secondary - Primary - Correl Sci NOS - CALGB-150007

PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy

Liu, M. , Pitcher, B. , Mardis, E. , Davies, S. , Snider, J. ... - AACR - Cancer Res. - 2012

Abstract - Secondary - Primary - Correl Sci NOS - CALGB-9741

PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)

Liu, Minetta C , Pitcher, Brandelyn N , Mardis, Elaine R ... - - NPJ Breast Cancer - 2016

Manuscript - Primary - Primary - Correl Sci NOS - CALGB-159905 , C9741

An mRNA Gene Expression–Based Signature to Identify FGFR1-Amplified Estrogen Receptor–Positive Breast Tumors

Luo, Jingqin , Liu, Shuzhen , Leung, Samuel , Gru, Alejandro A. ... - - J Mol Diagn - 2017

Manuscript - Secondary - Primary - Correl Sci NOS - ACOSOG-Z1031

Serial analysis of circulating tumor cells identifies four prognostic groups for novel risk-stratification in metastatic breast cancer (CALGB 40502/NCCTG N063H) (Alliance)

Magbanua, Mark Jesus M. , Hendrix, Laura H. , Hyslop, Terry ... - AACR-ALB - - 2020

Abstract - Secondary - Primary - Correl Sci NOS - CALGB-40502

Trajectory patterns of circulating tumor cells (CTC) in chemotherapy-treated metastatic breast cancer (MBC) patients predict poor clinical outcomes: CALGB 40502 / NCCTG N063H (Alliance)

Magbanua, Mark Jesus M. , Hendrix, Laura , Hyslop, Terry ... - SABCS - Cancer Res - 2017

Abstract - Secondary - Primary - Correl Sci NOS - CALGB-40502

Expanded genomic profiling of circulating tumor cells in metastatic breast cancer patients to assess biomarker status and biology over time (CALGB 40502 and CALGB 40503, Alliance)

Magbanua, Mark Jesus M. , Rugo, Hope S. , Wolf, Denise M. ... - - Clin. Cancer Res. - 2018

Manuscript - Secondary-not-in-original - Meta-Analysis - Correl Sci NOS - CALGB-40502 , CALGB-40503

Clinical significance of circulating tumor cells in hormone receptor-positive metastatic breast cancer patients who received letrozole with or without bevacizumab

Magbanua, Mark Jesus M. , Savenkov, Oleksandr , Asmus, Erik J. ... - - Clin. Cancer Res. - 2020

Manuscript - Secondary - Primary - Correl Sci NOS - CALGB-40503

Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response

Magbanua, Mark Jesus M. , Wolf, Denise M. , Yau, Christina ... - - Breast Cancer Res - 2015

Manuscript - Secondary - Primary - Correl Sci NOS - CALGB-150007

Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy.

Magbanua, Mark Jesus M , Hendrix, Laura H , Hyslop, Terry ... - - J. Natl. Cancer Inst. - 2020

Manuscript - Secondary - Primary - Correl Sci NOS - CALGB-40502

Tumor SPARC Microenvironment Signature and Plasma Levels in a Phase II Trial of Unresectable Stage IV Melanoma Treated With nab-Paclitaxel and Carboplatin: A Translational Study of NCCTG Trial N057E

Markovic, S. , Suman, V. , Treiu, V. , Liu, X. , Yeh, W. , Hwang, L. ... - - J. Clin. Oncol. - 2010

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N057E

PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer

Martin, M. , Prat, A. , Rodriguez-Lescure, A. , Caballero, R. ... - - Breast Cancer Res. Treat. - 2013

Manuscript - Secondary-not-in-original - Comprehensive - Correl Sci NOS - CALGB-9342 , CALGB-9840

Central Pathology Laboratory Review of HER2 and ER in Early Breast Cancer: An ALTTO Trial [BIG 2-06 / NCCTG N063D (Alliance)] Ring Study

McCullough, Ann E. , Dell'Orto, Patrizia , Reinholz, Monica M. ... - - Breast Cancer Res. Treat. - 2014

Manuscript - Secondary - Primary - Correl Sci NOS - N063D

A comprehensive analysis of clinical and tumor characteristics with BRAF and KRAS mutations status in adjuvant colon cancer trial N0147.

Mcwilliams, R. R. , Mahoney, M. R. , Sargent, D. J. , Nelson, G. D. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147

Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers

Miller, Christopher A. , Gindin, Yevgeniy , Lu, Charles ... - - Nat Commun - 2016

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - ACOSOG-Z1031

MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer

Miyoshi, Jinsei , Toden, Shusuke , Yoshida, Kazuhiro , Toiyama, Yuji ... - - Sci Rep - 2017

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147

Lobular breast cancer and NAC: Combined results from the NKI and I-SPY 1 trial

Mukhtar, R. A. , Lips, E. , Wesseling, J. , Livasy, C. , Yau, C. ... - - Cancer Res. - 2011

Abstract - Secondary - Primary - Correl Sci NOS - ACRIN-6657 , CALGB-150007

PCNA+ tumor associated macrophages are associated with M1 and M2 gene expression, and confer poor prognosis in the absence of anti-tumor immune environment

Mukhtar, R. A. , Wolf, D. , Tandon, V. , Zhu, J. , Lenburg, M. ... - - Cancer Res. - 2011

Abstract - Secondary - Primary - Correl Sci NOS - ACRIN-6657 , CALGB-150007

Vitamin D Status in Patients With Stage IV Colorectal Cancer: Findings From Intergroup Trial N9741

Ng, Kimmie , Sargent, Daniel J. , Goldberg, Richard M. ... - - J Clin Oncol - 2011

Manuscript - Secondary - Primary - Correl Sci NOS - N9741

Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance)

Niedzwiecki, Donna , Frankel, Wendy L. , Venook, Alan P. , Ye, Xing ... - - J. Clin. Oncol - 2016

Manuscript - Secondary - Primary - Correl Sci NOS - CALGB-150705 , C9581

Intrinsic subtype and response to paclitaxel in CALGB 9344 tissue microarrays

Nielsen, T. O. , Jewell, S. D. , Thor, A. D. , Gao, D. , Perou, C. M. ... - ASCO Breast - Breast Cancer Symposium - 2009

Abstract - Secondary - Primary - Correl Sci NOS - CALGB-159905 , C9344

A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer

Nielsen, Torsten O. , Parker, Joel S , Leung, Samuel , Voduc, David ... - - Clin Cancer Res - 2010

Manuscript - Secondary - Primary - Correl Sci NOS - CALGB-159905 , CALGB-9344

Blood-based biomarkers (BMs) in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI + bevacizumab (Bev), cetuximab (Cetux) or Bev + Cetux: Results from CALGB 80405

Nixon, Andrew B. , Sibley, Alexander B. , Hatch, Ace J. ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-80405

Genetic Variant Associated with Survival of Patients with Stage II-III Colon Cancer

Penney, Kathryn L. , Banbury, Barbara L. , Bien, Stephanie ... - - Clin. Gastroenterol. Hepatol. - 2019

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147

Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status

Rego, R L , Foster, N R , Smyrk, T C , Le, M , O'Connell, M J ... - - Br J Cancer - 2010

Manuscript - Secondary-not-in-original - Meta-Analysis - Correl Sci NOS - NCCTG-894651 , NCCTG-91-46-53

The concordance between NCCTGs and NSABPs C-myc FISH assays

Reinholz, M. , Dueck, A. , Lingle, W. , Ziegler, A. , Wiktor, A. ... - - J. Clin. Oncol. - 2008

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N9831

EGFR expression measured by quantitative immunofluorescense is associated with decreased benefit from trastuzumab in the adjuvant setting in the NCCTG (Alliance) N9831 trial.

Rimm, D. L. , Ballman, K. , Cheng, H. , Vassilakopoulou, M. , Chen, B. ... - - Cancer Res. - 2012

Abstract - Secondary - Primary - Correl Sci NOS - N9831

Identification of Potential Prognostic Biomarkers in Patients with Untreated, Advanced Pancreatic Cancer from a Phase III Trial (CALGB 80303)

Roberts, Andrew S. , Campa, Michael J. , Gottlin, Elizabeth B. ... - - Cancer - 2012

Manuscript - Secondary - Primary - Correl Sci NOS - CALGB-80303

Interim analysis of CALGB 150607: A pilot project to study the expression of MET and p53 in resected lung adenocarcinoma specimens

Salama, A. K. , Kratzke, R. A. , Richards, W. , Pang, H. ... - ASCO - J. Clin. Oncol. - 2010

Abstract - Secondary - Preliminary - Correl Sci NOS - CALGB-150607

An Interim Analysis Of CALGB 150607: Expression And Mutational Status Of c-MET, HGF, EGFR, KRAS, p53, c-CBL, And E-cadherin In Resected Lung Adenocarcinoma Specimens

Salgia, R. , Nallasura, V. , Pang, H. , Rolle, C. , Richards, W. ... - Chicago MSTO - Clin. Cancer Res. - 2012

Abstract - Secondary - Preliminary - Correl Sci NOS - CALGB-150607

High proliferation by the MCL35 assay is associated with inferior outcomes in patients treated with intensive regimens – a correlative study from the Alliance 50403 trial.

Scott, David W. , Pitcher, Brandelyn , Liu, Yi Tian , Boyle, Merrill ... - ICML - Hematol Oncol - 2017

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-50403

Association of RAS mutations with race in metastatic colorectal cancer CALGB 80405 (Alliance)

Sehdev, Amikar , Niedzwiecki, Donna , Venook, Alan P. ... - ASCO GI - J Clin Oncol - 2018

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-80405

Association study of the let-7 miRNA-complementary site variant in the 3’ untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 clinical trial)

Sha, Dan , Lee, Adam , Shi, Qian , Alberts, Steven R. ... - - Clin. Cancer Res. - 2014

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147

Association study of the let-7 microrna-binding site polymorphism in 3-untranslated region (UTR) of the KRAS gene in stage III colon cancers from adjuvant trial NCCTG N0147

Sha, Dan , Lee, Adam , Shi, Qian , Alberts, Steven R. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147

Prognostic Variables in Low and High Risk Stage III Colon Cancers Treated in Two Adjuvant Chemotherapy Trials

Sinicrope, Frank A. , Chakrabarti, Sakti , Laurent-Puig, Pierre ... - - Eur J Cancer - 2021

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147

Relative Contribution of Clinical and Molecular Features to Outcome Within Low and High Risk T and N Groups in Patients with Stage III Colon Cancers (Alliance)

Sinicrope, Frank A. , Huebner, Luke , Laurent-Puig, Pierre ... - ASCO - JCO - 2019

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147

Prognostic impact of KRAS and BRAFV600E mutations stratified by tumor site in resected stage III colon cancer patients treated with adjuvant mFOLFOX6 with or without cetuximab: NCCTG N0147 (Alliance)

Sinicrope, Frank A. , Mahoney, Michelle R. , Smyrk, Thomas C. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147

Prognostic impact of BRAF and KRAS mutations and their relationship to DNA mismatch repair (MMR) status in 2,686 stage III colon cancer patients (pts) treated in a phase III study of adjuvant FOLFOX +/- cetusimab: NCCTG N0147.

Sinicrope, Frank A. , Mahoney, Michelle R. , Smyrk, Thomas C. ... - ASCO - J. Clin. Oncol. - 2012

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147

Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy

Sinicrope, Frank A. , Mahoney, Michelle R. , Smyrk, Thomas C. ... - - J. Clin. Oncol - 2013

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-89803 , N0147

Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance)

Sinicrope, Frank A. , Mahoney, Michelle R. , Yoon, Harry H. ... - - Clin. Cancer Res. - 2015

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147

Association of DNA Mismatch Repair and Mutations in BRAF and KRAS with Survival after Recurrence in Stage III Colon Cancers from Phase III Adjuvant Chemotherapy Trials

Sinicrope, Frank A. , Shi, Qian , Allegra, Carmen J. ... - - JAMA Oncol - 2017

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147

Molecular markers and survival after recurrence in stage III colon cancers from NCCTG N0147 and NSABP C-08 adjuvant chemotherapy trials

Sinicrope, Frank A. , Shi, Qian , Allegra, Carmen Joseph ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147

Immunoscore provides prognostic information in low (T1-3N1) and high risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance)

Sinicrope, Frank A. , Shi, Qian , Hermitte, Fabienne ... - ASCO GI - J Clin Oncol - 2018

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147

Prognostic utility of immune markers and validation of Immunoscore in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance)

Sinicrope, Frank A. , Shi, Qian , Hermitte, Fabienne ... - ESMO GI - Annals of Oncology - 2017

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147

Association of an immunoscore with survival of stage III colon cancer (CC) patients treated with adjuvant FOLFOX (Alliance N0147)

Sinicrope, Frank A. , Shi, Qian , Hermitte, Fabienne , Heying, Erica ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147

Validation of tumor infiltrating lymphocytes (TIL) and tumor budding as predictors of prognosis in patients with stage III colon cancers treated in a FOLFOX-based adjuvant therapy trial: NCCTG N0147 (Alliance)

Sinicrope, Frank A. , Shi, Qian , Lee, Hee Eun , Foster, Nathan R. ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147

Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy (NCCTG N0147) (Alliance)

Sinicrope, Frank A. , Shi, Qian , Smyrk, Thomas C. ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary - Primary - Correl Sci NOS - NCCTG-N0147

Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated with Patient Outcomes

Sinicrope, Frank A. , Shi, Qian , Smyrk, Thomas C. ... - - Gastroenterology - 2015

Manuscript - Secondary - Primary - Correl Sci NOS - N0147

Molecular subtyping of colon cancers and distinct prognostic groups [NCCTG N0147 (Alliance)].

Sinicrope, Frank A. , Shi, Qian , Thibodeau, Stephen N. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary - Primary - Correl Sci NOS - N0147

Association Of Tumor Infiltrating Lymphocytes (Tils) With Molecular Subtype And Prognosis In Stage III Colon Cancers From A FOLFOX-Based Adjuvant Chemotherapy Trial: NCCTG N0147 (Alliance)

Sinicrope, Frank A. , Smyrk, Thomas C. , Foster, Nathan R. ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Secondary - Primary - Correl Sci NOS - NCCTG-N0147

Mutation-Specific Antibody Detects Mutant BRAFV600E Protein Expression in Human Colon Carcinomas

Sinicrope, Frank A. , Smyrk, Thomas C. , Tougeron, David ... - - Cancer - 2013

Manuscript - Secondary - Primary - Correl Sci NOS - N0147

Overall survival result and outcomes by KRAS, BRAF, and DNA mismatch repair in relation to primary tumor site in colon cancers from a randomized trial of adjuvant chemotherapy: NCCTG (Alliance) N0147.

Sinicrope, Frank A. , Yoon, Harry H. , Mahoney, Michelle R. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary - Primary - Correl Sci NOS - N0147

A low intraepithelial effector (CD3+):regulatory (FoxP3+) T-cell ratio predicts adverse outcome of human colon carcinoma

Sinicrope, Frank A , Rego, Rafaela L , Ansell, Stephen M ... - - Gastroenterology - 2009

Manuscript - Secondary - Primary - Correl Sci NOS - N0442

Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer

Sinicrope, Frank A , Shi, Qian , Hermitte, Fabienne , Zemla, Tyler J ... - - JNCI Cancer Spectr - 2020

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147

Cell Free DNA BRAF Mutation V600 Plasma Detection in Melanoma (Alliance) NCCTG N0879

Slostad, Jessica , Allred, Jake , Markovic, Svetomir , Erickson, Lori ... - SMR - Pigment Cell & Melanoma Research - 2018

Abstract - Secondary - Primary - Correl Sci NOS - N0879

Detection of the BRAFV600E protein in human colon carcinomas by a mutation-specific antibody

Smyrk, T. C. , Tougeron, D. , Thibodeau, S. N. , Singh, S. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147

Biomarkers for Risk Stratification in Patients with Previously Untreated Follicular Lymphoma Receiving Anti-CD20-Based Biologic Therapy

Sohani, Aliyah R. , Maurer, Matthew J. , Giri, Sharmila ... - - Am J Surg Pathol - 2021

Manuscript - Secondary-not-in-original - Meta-Analysis - Correl Sci NOS - CALGB-50402 , CALGB-50701 , CALGB-50803 , CALGB-50901

Interfollicular CD10 Expression and Follicular PD1 Tumor-infiltrating lymphocytes as biologic risk factors in patients with previously untreated follicular lymphoma receiving rituximab-based biologic therapy: An Alliance correlative science study (CALGB 50901, 50402, 50701, 50803, 50401)

Sohani, Aliyah R. , Pitcher, Brandy , Chadburn, Amy , Said, Jonathan ... - ASH - Blood - 2015

Abstract - Secondary-not-in-original - Meta-Analysis - Correl Sci NOS - CALGB-50401 , CALGB-50402 , CALGB-50701 , CALGB-50803 , CALGB-50901

Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer

Taieb, Julien , Le Malicot, Karine , Shi, Qian ... - - J. Natl. Cancer Inst - 2016

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147

Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials

Taieb, Julien , Malicot, Karine Le ... - ASCO - J Clin Oncol - 2015

Abstract - Secondary-not-in-original - Comprehensive - Correl Sci NOS - N0147

Transient state change, but not permanent subtype change, after HER2-targeted therapy for HER2-positive breast cancer (Alliance)

Tanioka, Maki , Parker, Joel S , Henry, Lynn N , Tolaney, Sara ... - SABCS - Cancer Res - 2019

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-40601

Influence of molecular alterations on site-specific (ss) time to recurrence (TTR) following adjuvant therapy in resected colon cancer (CC)

Wilcox, Ryan E. , Shi, Qian , Sinicrope, Frank A. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary - Primary - Correl Sci NOS - N0147

Patient-specific integrative pathway analysis using PARADIGM identifies key activities in I-SPY 1 breast cancer patients (CALGB 150007/150012; ACRIN 6657)

Wolf, D. , Yau, C. , Benz, S. , Vaske, C. , Stuart, J. , Roy, R. ... - SABCS - Cancer Res. - 2011

Abstract - Secondary - Primary - Correl Sci NOS - ACRIN-6657 , CALGB-150007

Gene expression changes associated with response to neoadjuvant chemotherapy are observed early in treatment: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

Wolf, D. , Yau, C. , Magbanua, M. , Boudreau, A. , Davis, S. , Haqq, C. ... - - Cancer Res. - 2012

Abstract - Secondary - Primary - Correl Sci NOS - CALGB-150007 , CALGB-150012

Deletions in HSP110 T17 and Patient Prognosis in Stage III Microsatellite Instable (MSI) Colon Cancers: Findings from CALGB 89803 and NCCTG N0147.

Wu, Christina , Shi, Qian , Tomsic, Jerneja , Meyers, Jeffrey ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - CALGB-89803 , NCCTG-N0147

Discovery of a new phosphoHER2+/FISH- molecular subtype of human breast cancer by functional pathway mapping

Wulfkuhle, J. , Pierobon, M. , Laird, J. , Espina, V. , Liotta, L. ... - - J. Clin. Oncol. - 2009

Abstract - Secondary - Primary - Correl Sci NOS - CALGB-150007

Protein pathway activation mapping of I-SPY 1 biopsy specimens identifies new network focused drug targets for patients with HR+/HER2– tumors

Wulfkuhle, J. , Yau, C. , Gallagher, R. , Wolf, D. , Calvert, V. ... - SABCS - Cancer Res. - 2012

Abstract - Secondary - Primary - Correl Sci NOS - CALGB-150007 , CALGB-150012

Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping

Wulfkuhle, Julia D. , Berg, Daniela , Wolff, Claudia , Langer, Rupert ... - - Clin. Cancer Res. - 2012

Manuscript - Secondary - Primary - Correl Sci NOS - CALGB-150007

Prognostic impact of specific KRAS mutations in codon 12 and 13 in 2,165 BRAF-wildtype colon cancers: Results from NCCTG N0147 (Alliance)

Yoon, H. H. , Tougeron, D. , Mahoney, M. R. , Shi, Q. , Sargent, D. J. ... - - European Journal of Cancer - 2013

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147

Inter-tumoral heterogeneity of CD3+ and CD8+ T-cell densities in the microenvironment of DNA mismatch repair-deficient colon cancers: implications for prognosis

Yoon, Harry H. , Shi, Qian , Heying, Erica N. , Muranyi, Andrea ... - - Clin. Cancer Res. - 2019

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147

CD3+ and CD8+ tumor-infiltrating lymphocyte (TIL) densities prognostically stratify DNA mismatch repair-deficient (dMMR) colon cancer patients (pts): NCCTG N0147 (Alliance)

Yoon, Harry H. , Shi, Qian , Heying, Erica N. , Muranyi, Andrea ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147

KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild type stage III colon cancers from an adjuvant chemotherapy trial (N0147 Alliance)

Yoon, Harry H. , Tougeron, David , Shi, Qian , Alberts, Steven R. ... - - Clin. Cancer Res. - 2014

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147

Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials

Zaanan, Aziz , Shi, Qian , Taieb, Julien , Alberts, Steven R. ... - - JCO Precis Oncol - 2020

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147

Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy

Zaanan, Aziz , Shi, Qian , Taieb, Julien , Alberts, Steven R. ... - - JAMA Oncol - 2018

Manuscript - Secondary-not-in-original - Primary - Correl Sci NOS - N0147

Is the predictive and prognostic impact of sporadic and familial microsatellite instable stage III colon cancer different? A pooled analysis of the PETACC8 and NCCTG N0147 (Alliance) trials

Zaanan, Aziz , Shi, Qian , Taieb, Julien , Alberts, Steven R. ... - ASCO - J Clin Oncol - 2019

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - NCCTG-N0147

Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients treated with adjuvant FOLFOX + cetuximab in the PETACC8 and N0147 adjuvant trials.

Zaanan, Aziz , Shi, Qian , Taieb, Julien , Alberts, Steven R. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary-not-in-original - Primary - Correl Sci NOS - N0147